CDC42-interacting protein 4 promotes metastasis of nasopharyngeal carcinoma by mediating invadopodia formation and activating EGFR signaling

Dong-Fang Meng, Ping Xie, Li-Xia Peng, Rui Sun, Dong-Hua Luo, Qiu-Yan Chen, Xing Lv, Lin Wang, Ming-Yuan Chen, Hai-Qiang Mai, Ling Guo, Xiang Guo, Li-Sheng Zheng, Li Cao, Jun-Ping Yang, Meng-Yao Wang, Yan Mei, Yuan-Yuan Qiang, Zi-Meng Zhang, Jing-Ping Yun, Bi-Jun Huang and Chao-Nan Qian

Abstract

Background: Nasopharyngeal carcinoma (NPC) is a common malignancy in Southern China and Southeast Asia. In this study, we investigated the functional and molecular mechanisms by which CDC42-interacting protein 4 (CIP4) influences NPC.

Methods: The expression levels of CIP4 were examined by Western blot, qRT-PCR or IHC. MTT assay was used to detect the proliferative rate of NPC cells. The invasive abilities were examined by matrigel and transwell assay. The metastatic abilities of NPC cells were revealed in BALB/c nude mice.

Results: We report that CIP4 is required for NPC cell motility and invasion. CIP4 promotes the activation of N-WASP that controls invadopodia formation and activates EGFR signaling, which induces downstream MMP2 (matrix metalloproteinase 2) upregulation. In addition, CIP4 could promote NPC metastasis by activating the EGFR pathway. In nude mouse models, distant metastasis was significantly inhibited in CIP4-silenced groups. High CIP4 expression is an independent adverse prognostic factor of overall survival (OS) and distant metastasis-free survival (DMFS).

Conclusion: We identify the critical role of CIP4 in metastasis of NPC which suggest that CIP4 may be a potential therapeutic target of NPC patients.

Keywords: NPC, CIP4, N-WASP, Invadopodia formation, EGFR/ERK/MMP-2 axis, Extracellular matrix degradation

Background

Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in southern China and Southeast Asia [1, 2]. The standard treatment modality for NPC is radiotherapy and platinum-based chemotherapy [3–5]. Significant improvements in therapeutic efficacy have been achieved with the extensive application of intensity-modulated radiotherapy (IMRT) together with concurrent chemotherapy [6, 7]. Distant metastasis is the main reason of treatment failure [8]. However, the molecular mechanisms underlying NPC metastasis remain poorly understood.

Metastasis is a complex series of steps in which cancer cells leave the original tumor and spread to other organs via the bloodstream, lymphatic system, or body cavities [9]. To move toward other organs, cancer cells must extend their plasma membrane forward at the front, forming the leading edge of the cell. Cells extend four different plasma membrane protrusions at the leading edge: lamellipodia, filopodia, podosomes and invadopodia [10–12]. These structures uniquely contribute to
cellular motility depending on specific circumstances [12]. Invadopodia are protrusions that allow focal degradation of the extracellular matrix to facilitate invasion through the tissues. Invadopodium extension in three dimensions (3D) requires force driven by actin polymerization. Demonstration of invadopodia is typically performed on two-dimensional (2D) surfaces coated with extracellular matrix proteins, where the invadopodia are present on the ventral surface [13–15]. Invadopodia degrade the extracellular matrix and require the delivery of vesicles containing matrix-degrading proteases, particularly membrane type 1 metalloproteinase (MT1-MMP) from the cellular plasma to invadopodial tip. These vesicles are targeted to invadopodia by the vesicle-tethering exocyst complex [16].

In mammals, the TOCA family (also named F-BAR proteins) includes three members: TOCA-1 (Transducer of CDC42-dependent actin assembly), CIP4 (CDC42-interacting protein 4), and FBP17 (formin-binding protein 17). CIP4 is implicated in clathrin-mediated endocytosis (CME), during which it senses and promotes membrane curvature through its F-BAR domain and binds to key regulators of actin dynamics (e.g., the nucleation promoting factor N-WASP) and endocytosis (e.g., dynamin) through their SH3 domain [17, 18]. Furthermore, CIP4 acts as an effector of the small GTPase CDC42 that promotes cell migration in breast cancer [19, 20].

Here, we demonstrate that by regulating invadopodia formation, assembly and extracellular matrix (ECM) degradation, CIP4 controls cell migration and invasion in response to EGFR signaling. We further demonstrate that CIP4 knock-down (KD) had no overt effect on tumor growth, but impaired the ability of distant metastasis in mouse xenograft models. Consistently, CIP4 expression is increased in NPC compared with nasopharyngeal mucosa. Evaluating the expression of CIP4 in primary tumors from 169 NPCs also revealed that high CIP4 protein levels correlate with worse overall survival (OS) and distant metastasis-free survival (DMFS) in NPC patients.

**Methods**

**Cell culture, cellular growth curve, and colony-formation assays**

The human nasopharyngeal carcinoma cell lines 5-8F and S1 were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS at 37 °C and 5% CO₂.

Cellular growth curves were plotted by using the cellular viability values assessed by the MTT method (Cell Titer 96 Aqueous One Solution Cell Proliferation Assay solution; Sigma). Briefly, 1000 cells/200 μl of medium were seeded into a 96-well plate (Corning) and cultured under normal conditions. At various time points after seeding, the cells in each well were stained with MTT (Sigma, M2128) for 3 h. Then, medium was discarded, and 200 μl of DMSO was added to each well and incubated for 10 min, and the OD490 was determined with a microplate reader.

For the colony-formation assays, 500 cells/2 ml were seeded into a 6-well plate (Corning). After 10 days, the cells were washed with phosphate-buffered saline (PBS), fixed with methanol for 15 min at room temperature, and stained with 1% crystal violet for 20 min. The colonies were counted. All experiments were independently repeated at least three times.

**RNA isolation and real-time quantitative reverse-transcription PCR (qPCR)**

Total RNA was extracted from cultured cell lines using TRIzol reagent (Invitrogen) and subjected to reverse transcription using a cDNA Synthesis Kit (Thermo, K1622). Real-time qPCR was performed using a SYBR FAST Universal qPCR Kit (KAPA, KK4602). The relative expression levels of the target genes were calculated as two power values of ΔCt (the Ct of GAPDH or CIP4 minus the Ct of the target gene). The sequences of the PCR primers used for amplification were as follows:

GAPDH forward, 5′-GTTCCTCTGACTTCAACA-3′;
GAPDH reverse, 5′-ACCACTCTGTGCTGTA GC-3′;
CIP4 forward, 5′-CGAATATGCGGCTCAACTGCA-3′;
CIP4 reverse, 5′-CCTGCGTTATCCATGTCCTGG -3′.

**Small interfering RNA transfection**

The negative control small interfering RNA (NC) was purchased from RIBOBIO, and siRNA sequences targeting human CIP4 are 5′-GCATGAAGGGCTGGCATAAA-3′ (si#1) and 5′-CCGAAGTGGAACAGGCTTA-3′ (si#2). Transient transfections of NPC cells were performed as described previously using the Lipofectamine RNAiMAX Reagent (Invitrogen) protocol. Briefly, 60 pmol siRNA was mixed with Opti-MEM Medium (Invitrogen) and incubated at room temperature for 15 min. Then, the mixture was added to the cells.

**Lentiviral transduction studies**

Cell lines stably expressing CIP4 short hairpin RNA (shRNA) or a negative control shRNA were purchased from FulenGen Co. Ltd. (Guangzhou, China). Lentiviruses were produced by 293T cells with one of the shRNA using X-tremeGENE DNA transfection reagents (Roche). Infectious lentiviruses were harvested 48 h after transfection and filtered through 0.45 mm filter
experiments were repeated independently three times.

and invaded cells were counted under a microscope. Both harvested Biocoats were then stained with crystal violet.

Animal experiments
Female athymic mice (Beijing Charles River Laboratory Animal Center) were purchased at 4–5-weeks-of-age and maintained under a specific pathogen-free environment. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Sun Yat-Sen University Cancer Center.

Migration and invasion assays
Migration assays were conducted with Biocoat without Matrigel (Corning, Life sciences), and invasion assays were performed with Biocoat with Matrigel (Corning, Life sciences). Following the manufacturer's instructions. The harvested Biocoats were then stained with crystal violet, and invaded cells were counted under a microscope. Both experiments were repeated independently three times.

Human tissue samples
To compare the mRNA expression levels of CIP4 among different stages of NPC development, 19 non-cancerous nasopharyngeal mucosa and 15 primary NPCs were obtained at the Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center (SYSUCC). In total, 169 formalin-fixed and paraffin-embedded NPC specimens were obtained from patients at SYSUCC pathologically diagnosed between February 2006 and December 2009. The 169 cases of NPC with sufficient follow-up data qualified for analyses after immunohistochemical (IHC) staining for CIP4. All human tissue samples were obtained with patient consent and the approval of the Institutional Clinical Ethics Review Board at SYSUCC.

In IHC analysis of CIP4, the paraffin-embedded slices were deparaffinized, rehydrated, and blocked in 5% bovine serum albumin (BSA) at room temperature for 20 min. The samples were incubated with rabbit
polyclonal antibody against CIP4 (ab108313, Abcam) at a dilution of 1:100 at 4 °C overnight followed by horse-radish peroxidase (HRP) anti-rabbit immunoglobulin at a concentration of 1:100 for 30 min at 37 °C. The primary antibodies were detected with 3, 3-diaminobenzidine substrate visualization and counterstaining with hematoxylin (GTVision III Detection System/Mo & Rb). For each tumor, we determined a proportion score and an intensity score. Cytoplasmic and membranous staining intensity were categorized as follows: absent staining as 0, weak as 1, moderate as 2, and strong as 3. The percentage of stained cells was categorized as no staining = 0, 1–10% of stained cells = 1, 11–50% = 2, 51–80% = 3, and 81–100% = 4. The proportion and intensity were then multiplied to produce a total score ranging from 0 to 12. The median score of CIP4 (score = 4) was used as the cutoff value to divide the patients into high (≥ median) and low (≤ median) CIP4 expression groups.

Statistical analysis
Student’s t-test was used to compare two independent groups of data. The median IHC staining score was used as a cut-off value to divide the patients into low and high CIP4 expression groups. Chi-squared tests were applied to analyze the relationship between CIP4 expression and clinicopathological status. The significance of several variables for survival was analyzed using the Cox regression model in a multivariate analysis. *P*-value < 0.05 was considered statistically significant in all cases.

Results
CIP4 is highly expressed in NPC tissues and is associated with poor prognosis
To investigate the underlying clinical significance of CIP4, the CIP4 expression level with clinicopathological features in 169 NPCs (informative IHC cases) was analyzed (Fig. 1a). High CIP4 expression was significantly associated with M stage and prognosis (Table 1).
Multivariate analyses of different prognostic parameters revealed that high CIP4 expression was an independent, unfavorable prognostic indicator for OS and DMFS (Table 2). In the Kaplan-Meier analysis, OS and DMFS were increased for patients with low CIP4 expression compared with those with high CIP4 expression (Fig. 1b). CIP4 mRNA levels were also increased in NPC tissues compared with nasopharyngeal mucosa (Fig. 1c). These data collectively demonstrate a close correlation between CIP4 expression level and poor patient outcomes, implying an important role for CIP4 in NPC progression.

Knocking-down CIP4 inhibits the migration and invasion of highly metastatic NPC cells without influencing general cell growth or contact-independent cell growth

To further confirm whether CIP4 influences cell mobility in migration and invasion without affecting tumor formation, CIP4 was knocked down in two highly metastatic cell lines (5-8F and S18) via RNA interference (RNAi) with two shRNAs targeting CIP4 (CIP4-KD1 and CIP4-KD2). A scramble shRNA was used as a control (CIP4-CON). Western blotting revealed a significant reduction in CIP4 protein levels (Fig. 2a).

Functional assays of cell growth curves and colony formation revealed that the NPC cell growth rate and contact-independent cell growth were not significantly altered in CIP4 KD cells compared with control cells (Fig. 2b, c, and d).

CIP4 promotes NPC cell migration and invasion in vitro

To examine the causal role of CIP4 in NPC cell motility, we used migration assays to evaluate cell migration in CIP4 control and KD cells. CIP4-KD cells exhibited reduced migration compared with controls (Fig. 3a). Next, we compared the effects of CIP4-KD on the invasive potential of 5-8F and S18 cells using Matrigel-

### Table 1 Association between expression of CIP4 and clinicopathological characteristics in 169 NPC patients

| Clinical factor                  | Cases (n = 169) | High (n = 83) | Low (n = 86) | P value |
|----------------------------------|-----------------|---------------|--------------|---------|
| Gender                           |                 |               |              |         |
| Male                             | 128             | 63            | 65           | 0.961   |
| Female                           | 41              | 20            | 21           |         |
| Ages (years)                     |                 |               |              |         |
| < 45                             | 79              | 39            | 40           | 0.951   |
| ≥ 45                             | 90              | 44            | 46           |         |
| T stage                          |                 |               |              |         |
| T1-2                             | 49              | 22            | 27           | 0.484   |
| T3-4                             | 120             | 61            | 59           |         |
| N stage                          |                 |               |              |         |
| N0-1                             | 89              | 41            | 48           | 0.404   |
| N2-3                             | 80              | 42            | 38           |         |
| M stage                          |                 |               |              |         |
| M0                               | 160             | 75            | 85           | 0.035   |
| M1                               | 9               | 8             | 1            |         |
| Clinical stage                   |                 |               |              |         |
| I-II                             | 17              | 6             | 11           | 0.229   |
| III-IV                           | 152             | 77            | 75           |         |
| WHO histological classification  |                 |               |              |         |
| Type 2                           |                 |               |              |         |
| Differentiated                   | 8               | 2             | 6            | 0.300   |
| Undifferentiated                 | 161             | 81            | 80           |         |
| Local-regional relapse           |                 |               |              |         |
| No                               | 166             | 81            | 85           | 0.975   |
| Yes                              | 3               | 2             | 1            |         |
| Distant metastasis               |                 |               |              |         |
| No                               | 156             | 73            | 83           | 0.072   |
| Yes                              | 13              | 10            | 3            |         |
| Progression                      |                 |               |              |         |
| No                               | 147             | 66            | 81           | 0.005   |
| Yes                              | 22              | 17            | 5            |         |
| Death                            |                 |               |              |         |
| No                               | 142             | 63            | 79           | 0.005   |
| Yes                              | 27              | 20            | 7            |         |

Statistical significance (p < 0.05) is shown in bold and italic.

### Table 2 Univariate and multivariate analyses of different prognostic parameters in NPC patients

| Variables          | Univariate analysis | Multivariate analysis |
|--------------------|---------------------|-----------------------|
|                    | HR                  | Cl                    | P        | HR                  | Cl                    | P        |
| OS                 |                     |                       |         |                     |                       |         |
| Gender             | 2.763               | 0.832–9.181           | 0.097   | ...                 | ...                   | ... |
| Age                | 2.841               | 1.198–6.734           | ...     | 5.148               | 1.933–13.707          | 0.001   |
| T stage            | 1.317               | 0.554–3.129           | 0.533   | ...                 | ...                   | ... |
| N stage            | 1.745               | 0.810–3.761           | 0.155   | ...                 | ...                   | ... |
| M stage            | 9.441               | 3.769–23.647          | <0.001  | 14.195              | 4.642–43.407          | <0.001  |
| Clinical stage     |                     |                       |         |                     |                       |         |
| CIP4               | 1.137               | 1.043–1.240           | 0.004   | 1.111               | 1.015–1.216           | 0.022   |
| DMFS               |                     |                       |         |                     |                       |         |
| Gender             | 4.019               | 0.523–30.911          | 0.181   | ...                 | ...                   | ... |
| Age                | 1.451               | 0.475–4.436           | 0.514   | ...                 | ...                   | ... |
| T stage            | 0.666               | 0.218–2.037           | 0.476   | ...                 | ...                   | ... |
| N stage            | 1.908               | 0.624–5.832           | 0.257   | ...                 | ...                   | ... |
| M stage            | 13.355              | 4.058–43.955          | <0.001  | 8.565               | 2.495–29.401          | 0.001   |
| Clinical stage     |                     |                       |         |                     |                       |         |
| CIP4               | 1.199               | 1.046–1.374           | 0.009   | 1.159               | 1.006–1.336           | 0.041   |

Abbreviations: OS overall survival, DMFS distant metastasis-free survival, CI confidence interval, HR hazard ratio. Statistical significance (p < 0.05) is shown in bold and italic.
coated transwell chambers. Interestingly, both 5-8F and S18 KD cells exhibited severe defects in cell invasion compared with their respective controls (Fig. 3b and d). Together, these results suggest that CIP4 positively regulates NPC cell migration and invasion through the ECM.

CIP4 regulates invadopodia assembly through activation of N-WASP

The Arp2/3 complex and neural Wiskott–Aldrich syndrome protein (N-WASP; encoded by WASL) are essential components of invadopodia, which regulate actin polymerization in the early phase of invadopodium assembly [28]. Lorenz and colleagues previously measured and directly imaged N-WASP activity in vivo by using FRET microscopy and observed that N-WASP was involved in the cytoskeleton reorganization of invadopodia of migrating carcinoma cells. N-WASP can be activated by many upstream factors, including Cdc42, PIP2, or phosphorylation, and it is likely that different cell responses are regulated by different upstream activators [29]. Because CDC42 interacts with N-WASP and facilitates the nuclear translocation of EGFR [30], we investigated the role of CIP4 EGF-induced N-WASP activation. N-WASP phosphorylation was decreased in CIP4-silenced cells compared with control cells (Fig. 4a). Previous research showed a rapid, transient increase in acceptor photobleaching fluorescence resonance energy transfer (apFRET) efficiency between CIP4 and N-WASP after EGF stimulation in the fluorescence resonance energy transfer assay [20]. In the presence of EGF, control 5-8F cells increased the phosphorylation of N-WASP at 1 min (Fig. 4b). Knockdown of CIP4 decreased the basal level of N-WASP phosphorylation in 5-8F cells (Fig. 4c). These results suggest that CIP4 significantly altered

---

**Fig. 2** Suppression of CIP4 expression has no effect on growth in NPC cells in vitro. a Decreased expressions of CIP4 were respectively confirmed by Western blotting in CIP4-silenced 5-8F and S18 cells compared with scrambled shRNA control cells. b Cell growth rates between CIP4-silenced and scrambled shRNA control cells were compared by MTT assay. c and d The colony formation assays were performed to determine the effect of growth in CIP4 knockdown and control cells. N.S. means no significance. The data are presented as the mean ± S.D. (from triplicates).
invadopodia assembly by affecting the level of activated N-WASP.

CIP4 has important functions in invadopodia formation and ECM degradation

N-WASP is an actin-regulatory protein associated with invadopodium markers, including ARP2/3 and cortactin. These proteins then form a complex with the small GTPase CDC42 [31]. To determine whether CIP4 played an important role in invadopodia formation, NPC cells were plated on glass-bottom dishes of Oregon Green® 488 Conjugate-labeled gelatin and incubated overnight to allow invadopodia formation. As shown in Fig. 5a and b, the formation of invadopodia was visualized by co-immunostaining cells for filamentous actin (F-actin) using fluorescently conjugated phalloidin (red) and invadopodium-associated protein cortactin (blue). Dot-like ECM degradation (loss of green color) under the cell was also observed (see arrowhead).

To examine the role of CIP4 in invadopodia formation by NPC cells, we quantified the percentage of cells with invadopodia and the distribution of the number of invadopodia per cell after treatment knockdown with control or CIP4 siRNA. We observed a significantly reduced percentage of cells with invadopodia and fewer invadopodia per cell in CIP4-siRNA-treated cells. To evaluate the size and function of invadopodia, we quantified the area of gelatin degradation per cell and found significantly less gelatin degradation after CIP4 silencing (Fig. 5c and d).

CIP4 regulates EGFR signaling and promotes MMP-2 expression in NPC cells

TOCA family members control early events of epidermal growth factor receptor (EGFR) clathrin-mediated
endocytosis (CME) and trafficking [17, 32], and EGFR is widely expressed in NPC [33]. To assess the effects of CIP4 on EGFR signaling in NPC cells, we performed a 20-min time course of EGF treatment. EGF treatment of CIP4 CON and KD cells led to rapid phosphorylation of EGFR (pEGFR; Y1068) that was sustained throughout the time course. CIP4 KD cells exhibited no overt defects in EGF-induced pEGFR levels compared with control cells (Fig. 6a and b).

To address whether CIP4 regulates EGFR signaling to downstream pathways, we profiled EGF-induced phosphorylation of the activation loop sites (S473) in Akt (pAkt) and Erk kinases (pErk) in CIP4 CON and KD cells. EGF-induced phosphorylation of Akt (S473) did not differ in CIP4 CON and KD cells (Fig. 6c and d). In contrast, CIP4 KD resulted in a less sustained phosphorylation of Erk with EGF treatment (Fig. 6e).

The maturation process for invadopodia involves the recruitment and activation of multiple pericellular proteases that facilitate ECM degradation, such as zinc-regulated metalloproteases (matrix metalloprotease 2 (MMP2), MMP9, MT1-MMP) [34, 35]. Therefore, we investigated whether CIP4 KD effects the expression of MMPs. Immunoblotting revealed a significant reduction in MMP-2 but not MMP-9 in CIP4 KD cells (Fig. 6f).

Taken together, these results suggest that CIP4 modulates the kinetics of EGFR signaling and promotes MMP-2 expression in NPC cells.

CIP4 silencing impairs NPC metastasis in vivo

To evaluate the effects of CIP4 on tumor metastasis in vivo, the same amount of shRNA-transfected cells (5-8F-shRNA-CIP4-1, 5-8F-shRNA-CIP4-2) and their control were injected into nude mice intravenously through the tail vein. After 6 weeks, the mice were euthanized, and metastatic lung nodules were counted (Fig. 7a). Although there was no difference in average tumor mass between CIP4 KD and controls (Fig. 7b), scoring of the numbers of metastases from hematoxylin and eosin (H&E)-stained lung tissue sections revealed a significant reduction in incidence compared with control mice (Fig. 7c). To extend these findings, we utilized a popliteal lymph node (LN) metastasis model. The spontaneous metastasis experiments indicate that the popliteal LN
metastasis rate was significantly reduced from 70% (21/30) to 20% (6/30) or 26.7% (8/30) via suppression of CIP4 expression in NPC cells (Fig. 7d). Together these results corroborate the importance of CIP4 in the regulation of NPC tumor metastasis in vivo.

**Discussion**

The main obstacle in the current clinical management of NPC is metastasis [36]. Given its high metastasis rate, NPC cell motility has been linked to the formation of different types of cellular membrane protrusions.
Fig. 6 (See legend on next page.)
Lamellipodia extend long distances through the extracellular matrix and pull cell through the tissues. In filopodia, actin polymerization directly pushes the cytomembrane forward [37–39]. Invadopodia deliver matrix-degrading metalloproteases to clear a path for cells through the extracellular matrix [40]. Our functional studies confirmed that silencing CIP4, the regulator of invadopodia, impaired MMPs-mediated degradation of collagen to generate the ECM tracks.

CIP4 is an F-BAR protein that regulates actin-based cell motility [30]. Roles of CIP4 in cell migration have been described in neuronal, B lymphoma cells and breast cancer [20, 41, 42]. However, we demonstrate the role of CIP4 in the regulation of invadopodia formation, cell-migration and cell-ECM degradation during NPC metastatic events in the present study. We show that inducible silencing of CIP4 results in defects in EGFR signaling and impaired motility and invasion of NPC cells. We also tested the effects of CIP4 silencing on NPC metastasis in tumor xenograft assays and observed a key role for CIP4 in NPC metastasis. Importantly, our study also profiled CIP4 expression in human nasopharyngeal carcinoma patients, which revealed links between high CIP4 levels and worse prognosis. Together with our findings in NPC models, these studies identify CIP4 as a key signaling hub in NPC metastasis.

N-WASP and Cdc42 are critical for the formation of invadopodia, which are specialized cytoskeletal structures that combine localized actin protrusion with matrix metalloproteinases (MMPs) secretion to degrade extracellular matrices and allow invasion [43, 44]. The formation of invadopodia requires the activation of the Cdc42–N-WASP pathway [45]. We found that CIP4 is fully indispensable in mediating the activation of a CDC42/N-WASP, a function likely fulfilled by the other members of the family. Instead, CIP4 is essential for the formation of invadopodia.

Since the majority of NPCs express high levels of EGFR, there has been considerable interest in testing EGFR signaling. Several previous studies have functionally linked CIP4 to EGFR trafficking and downstream signaling to pathways controlling cell motility and invasiveness [32, 46]. In the present study, we showed that silencing CIP4 in NPC cell lines resulted in impaired EGFR signaling to ERK, whereas high CIP4 expression promoted activation of the EGFR/ERK/MMP-2 axis in...
NPC cells. Others have also reported a role for CIP4 in promoting Src activation and Cadherin switching in mammary epithelial cells treated with EGF or TGFβ [32].

Conclusions
In summary, CIP4 plays an important role in the promotion of NPC metastasis by mediating invadopodia formation and activating the EGFR pathway, which may lead to the identification of a new therapeutic target for distant metastasis of NPC.

Abbreviations
afpFRET: Acceptor photobleaching fluorescence resonance energy transfer; CIP4: CDC42-interacting protein 4; CIP4: CDC42-interacting protein 4; CME: Clathrin-mediated endocytosis; DMFS: Distant metastasis-free survival; ECM: extracellular matrix; FBP17: Formin-binding protein 17; H&E: Hematoxylin and eosin; IHC: Immuno-histochemical; IMRT: Intensity-modulated radiotherapy; MMP2: Matrix metalloproteinase 2; MT1-MMP: Membrane type 1 metalloproteinase; NPC: Nasopharyngeal carcinoma; N-WASP: Wiskott–Aldrich syndrome protein; OS: Overall survival; RNAi: RNA interference; TOCA-1: Transducer of CDC42-dependent actin assembly

Acknowledgments
Not applicable.

Funding
This work was supported by grants from the National Natural Science Foundation of China (No. 81672872, No. 81272340 and No. 81472386 to CQ, No. 81572901 to BH, No. 81572848 to LG, No. 81402248 to DZL, and No. 81372527 and No. 81572406 to JY), the High Technology National Research and Development Program of China (863 Program) (No. 2012AA02A501 to CQ), the Science and Technology Planning Project of Guangdong Province, China (No. 2014B020212017, No. 2014B050504004 and No. 2015B050501005 to CQ), and No. 2014A040209024 to BH), and the Provincial Natural Science Foundation of Guangdong, China (No. 2016A030311011 to CQ).

Availability of data and materials
Not applicable.

Authors’ contributions
All authors had full access to the data and participated in the design, analysis and interpretation of the data. D-FM and C-NQ were responsible for drafting the manuscript. All of the authors reviewed the manuscript before submission. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
All animal experiments were approved by the Institutional Animal Care and Use Committee of the Sun Yat-Sen University Cancer Center. All human tissue samples were obtained with patient consent and the approval of the Institutional Clinical Ethics Review Board at Sun Yat-Sen University Cancer Center.

Author details
1 State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China. 2Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China. 3Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China. 4Radiotherapy Department, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou 510095, China.

Received: 28 September 2016 Accepted: 23 December 2016

Published online: 28 January 2017

References
1. Cao SM, Xu YJ, Lin GZ, Huang QH, Wei KR, Xie SH, Liu Q. Estimation of cancer burden in Guangdong Province, China in 2009. Chin J Cancer. 2015;34:594–601.
2. Poh SS, Chua ML, Wee JT. Carcinogenesis of nasopharyngeal carcinoma: an alternate hypothetical mechanism. Chin J Cancer. 2016;35:9.
3. Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer. 2005;103:22–31.
4. Lee AW, Zee WM, Au SS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005;61:107–16.
5. Suarez C, Rodrigo JP, Rinaldo A, Langendijk JA, Shaar AH, Ferlito A. Current treatment options for recurrent nasopharyngeal cancer. Eur Arch Otorhinolaryngol. 2010;267:1811–24.
6. Lee N, Xia P, Quivey JM, Sultanek K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu K. Inhibition of breast cancer growth by an antagonist of the activated SRC and EGFR signaling pathways. Cancer Res. 2007;67:7737–44.
7. Bajtat B, Audry H, Bourhis J, Chan AT, Orat H, Chua DT, Kjong DL, Al-Sarraf M, Chi KH, Hareyama M, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: a randomized trial of radiation therapy versus chemoradiation therapy. J Clin Oncol. 2005;23:2256–63.
8. Lee AW, Ng WT, Chan YH, Sze H, Chan C, Lam TH. The battle against nasopharyngeal cancer. Radiother Oncol. 2012;104:22–7.
9. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127:679–95.
10. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz FR. Cell migration: rollin’ rats with Lex and Astro. Science. 2003;300:1704–9.
11. Bucicione R, Orth JD, McNiven MA. Foot and mouth: podosomes, invadopodia and circular donut ruffles. Nat Rev Mol Cell Biol. 2004;5:647–57.
12. Alblazi KM, Sar CH. Cellular protrusions—lamellipodia, filopodia, invadopodia and podosomes—and their roles in progression of orofacial tumours: current understanding. Asian Pac J Cancer Prev. 2015;16:2187–91.
13. Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol. 2009;10:445–57.
14. Schoumacher M, Goldman RD, Louvard D, Vignjevic DM, Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J Cell Biol. 2010;189:541–56.
15. Wolf K, Friedl P. Mapping proteolytic cancer cell-extracellular matrix interactions. Curr Opin Struct Biol. 2006;16:289–98.
16. Lizarraga F, Poelclic Ox, Romao M, Montagnac G, Le Dez G, Bonne I, Rigail G, Raposo G, Chavrier P. Diaphanous-related formins are required for invadopodia formation and invasion of breast tumor cells. Cancer Res. 2009;69:2792–800.
17. Itoh T, Erdmann KS, Roux A, Habermann B, Wemer H, De Camilli P. Dynamin and the actin cytoskeleton cooperatively regulate plasma membrane invagination by BAR and F-BAR proteins. Dev Cell. 2005;9:791–804.
18. Tian L, Nelson DL, Stewart DM. Cdc42-interacting protein 4 mediates binding of the Wiskott-Aldrich syndrome protein to microtubules. J Biol Chem. 2000;275:7854–61.
19. Aspenstrom P. Roles of F-BAR/PCH proteins in the regulation of membrane dynamics and actin reorganization. Int Rev Cytol Mol Biol. 2009;272:1–31.
20. Ichihara K, Arvanitis S, Hartig SM, Jensen SA, Bechill J, Marzouk S, Yu J, Frost JA, Corey SJ. Cdc42-interacting protein 4 promotes breast cancer cell invasion and formation of invadopodia through activation of N-Wasp. Cancer Res. 2010;70:8347–56.
21. Bowden ET, Barth M, Thomas D, Glazer R, Mueller SC. An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene. 1999;18:4435–40.
22. Onodera Y, Hashimoto S, Hashimoto A, Morishige M, Mazaki Y, Yamada A, Ogawa E, Adachi M, Sakurai T, Manabe T, et al. Expression of AMAP1, an orphan G protein coupled receptor, in human prostate cancer cell lines. Cancer Res. 2002;62:7362–7.
23. Ichihara K, Arvanitis S, Hartig SM, Jensen SA, Bechill J, Marzouk S, Yu J, Frost JA, Corey SJ. Cdc42-interacting protein 4 promotes breast cancer cell invasion and formation of invadopodia through activation of N-Wasp. Cancer Res. 2010;70:8347–56.
24. Bowden ET, Barth M, Thomas D, Glazer R, Mueller SC. An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene. 1999;18:4435–40.
25. Ichihara K, Arvanitis S, Hartig SM, Jensen SA, Bechill J, Marzouk S, Yu J, Frost JA, Corey SJ. Cdc42-interacting protein 4 promotes breast cancer cell invasion and formation of invadopodia through activation of N-Wasp. Cancer Res. 2010;70:8347–56.
26. Bowden ET, Barth M, Thomas D, Glazer R, Mueller SC. An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene. 1999;18:4435–40.
27. Ichihara K, Arvanitis S, Hartig SM, Jensen SA, Bechill J, Marzouk S, Yu J, Frost JA, Corey SJ. Cdc42-interacting protein 4 promotes breast cancer cell invasion and formation of invadopodia through activation of N-Wasp. Cancer Res. 2010;70:8347–56.
28. Bowden ET, Barth M, Thomas D, Glazer R, Mueller SC. An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene. 1999;18:4435–40. © 2017 The Author(s). Published by Wiley. All rights reserved.
regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene. 2009;28:3197–208.

24. Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, Dittey J, Tsarfaty I, Hudson E, Jackson DG, Pettolo D, et al. Preparing the “soil”: the primary tumor induces vascular reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res. 2006;66:10365–76.

25. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Dui A, Peng LX, Lu WH, Zhang Z, Pettolo D, et al. Serglycin is a thernostatic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011;71:3162–72.

26. Bao YN, Cao X, Luo DH, Sun R, Peng LX, Wang L, Yan YP, Zheng LS, Xie P, Cao Y, et al. Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis. Cell Cycle. 2014;13:1958–69.

27. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McLanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.

28. Ayala I, Giacchetti G, Caldieri G, Attanasio F, Maringio S, Tete S, Polishchuk R, Castronovo V, Buccione R. Faciogenital dysplasia protein Fgd1 regulates invadopodia biogenesis and extracellular matrix degradation and is up-regulated in prostate and breast cancer. Cancer Res. 2009;69:747–52.

29. Lorenz M, Yamaguchi H, Wang Y, Singer RH, Condeelis J. Imaging sites of N-wasp activity in lamellipodia and invadopodia of carcinoma cells. Curr Biol. 2004;14:697–703.

30. Hu J, Troglio F, Mukhopadhayay A, Everingham S, Kwok E, Scita G, Craig AW. F-BAR-containing adaptor CIP4 localizes to early endosomes and regulates Epidermal Growth Factor Receptor trafficking and downregulation. Cell Signal. 2009;21:1686–97.

31. Ridley AJ. Life at the leading edge. Cell. 2011;145:1012–22.

32. Rolland Y, Marighetti P, Malnemo C, Confalonieri S, Luise C, Ducano N, Palamidessi A, Bui S, Kajho H, Troglio F, et al. The CDC42-interacting protein 4 controls epithelial cell cohesion and tumor dissemination. Dev Cell. 2014;30:553–68.

33. Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol. 2015;12:111–26.

34. Styli S, Kaye AH, Lock P. Invadopodia at the cutting edge of tumour invasion. J Clin Neurosci. 2008;15:275–37.

35. Linder S. The matrix corroded: podosomes and invadopodia in extracellular cell cohesion and tumor dissemination. Dev Cell. 2011;24:1739–41.

36. Wang W, Li X, Zhang W, Li W, Yi M, Yang J, Zeng Z, Colvin Wanshura LE, Ayala I, Giacchetti G, Caldieri G, Attanasio F, Mariggio S, Tete S, Polishchuk R, Castronovo V, Buccione R, et al. The CDC42-interacting protein 4 controls epithelial cell cohesion and tumor dissemination. Dev Cell. 2014;30:553–68.

37. Wang W, Li X, Zhang W, Li W, Yi M, Yang J, Zeng Z, Colvin Wanshura LE, Ayala I, Giacchetti G, Caldieri G, Attanasio F, Mariggio S, Tete S, Polishchuk R, Castronovo V, Buccione R, et al. The CDC42-interacting protein 4 controls epithelial cell cohesion and tumor dissemination. Dev Cell. 2014;30:553–68.

38. Zhang M, Song A, Lai S, Qiu L, Huang Y, Chen Q, Zhu B, Xu D, Zheng JC. Applications of stripe assay in the study of CXCL12-mediated neural progenitor cell migration and polarization. Biomaterials. 2015;72:163–71.

39. Wen Q, Li J, Wang W, Xie G, Xu L, Luo J, Chu S, Shi L, Li D, Huang D, Fan S. Increased expression of flotillin-2 protein as a novel biomarker for lymph node metastasis in nasopharyngeal carcinoma. PLoS One. 2014;9:e101676.

40. Zhang L, Sun J, Liu Z, Dai Y, Luo Z, Jiang X, Li Z, Li Y, Cao P, Zhou Y, et al. Mesenchymal stem cells regulate cytoskeletal dynamics and promote cancer cell invasion through low dose nitric oxide. Curr Mol Med. 2014;14:749–61.

41. Saengsawang W, Taylor KL, Lumbard DC, Mitek K, Price A, Pietila L, Gomez TM, Dent EW. CIP4 coordinates with phospholipids and actin-associated proteins to localize to the protruding edge and produce actin ribs and veils. J Cell Sci. 2013;126:2411–20.

42. Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM, Eddy R, Condeelis J. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and collin. J Cell Biol. 2005;168:441–52.

43. Weaver AM. Invadopodia: specialized cell structures for cancer invasion. Clin Exp Metastasis. 2006;23:97–105.

44. Yamaguchi H, Lorenz M, Kerpiai S, Sarmentio C, Coniglio S, Symons M, Segall J, Eddy R, Miki H, Takenawa T, Condeelis J. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and collin. J Cell Biol. 2005;168:441–52.